Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins
Quick Facts
- Publication title: Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins
- Journal: Biosens Bioelectron
- Year: 2024
- DOI: 10.1016/j.bios.2024.116748
- PMID/PMCID: 39276441
Research overview
In this work, we developed a high-throughput microdroplet-enhanced chip (MEC) platform, which utilizes thousands of individual microchambers (∼pL) as reactors, accelerating the detection efficiency of the CRISPR/Cas systems and increasing the sensitivity by up to 100-fold (aM level). Nevertheless, simultaneous detection of multiple EVs markers still presents significant technical challenges.
Key findings
Extracellular vesicles (EVs) are considered as promising candidates for predicting patients who respond to immunotherapy.
Nevertheless, simultaneous detection of multiple EVs markers still presents significant technical challenges.
In this work, we developed a high-throughput microdroplet-enhanced chip (MEC) platform, which utilizes thousands of individual microchambers (∼pL) as reactors, accelerating the detection efficiency of the CRISPR/Cas systems and increasing the sensitivity by up to 100-fold (aM level).
911) than the individual marker for the efficacy prediction of immunotherapy.
Echo Biotech Role
Echo Biotech contributed co-authored scientific research.
Related platforms: Corporate Research / Scientific Publications
Related services and capabilities: Co-authored Scientific Research
References
Original publication: Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins Biosensors & bioelectronics. 2024. DOI: 10.1016/j.bios.2024.116748. PMID/PMCID: 39276441.